• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Iovance Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update

    7/3/25 4:05:53 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IOVA alert in real time by email
    false 0001425205 0001425205 2025-06-30 2025-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

     Current Report

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): June 30, 2025

     

    IOVANCE BIOTHERAPEUTICS, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware
    (State of Incorporation)
     
    001-36860   75-3254381
    Commission File Number   (I.R.S. Employer Identification No.)
         
    825 Industrial Road, Suite 100    
    San Carlos, California   94070
    (Address of Principal Executive Offices)   (Zip Code)
         
    (650) 260-7120
    (Registrant’s Telephone Number, Including Area Code)
     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

     

    ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

     

    ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading
    Symbol(s)
    Name of each exchange on which
    registered
    Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Market, LLC

     

     

     

     

     

      

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    As previously disclosed, on June 10, 2025, Jean-Marc Bellemin notified Iovance Biotherapeutics, Inc. (the “Company”) that he would be resigning as Chief Financial Officer and Principal Financial Officer and Principal Accounting Officer of the Company to pursue other opportunities, effective July 10, 2025. On June 30, 2025, the Company and Mr. Bellemin mutually agreed that Mr. Bellemin would separate from the Company, effective June 30, 2025.

     

    Effective as of June 30, 2025, Matthew W. Rosinack, the Company’s Senior Vice President, Finance, was appointed as the Company’s interim Principal Financial Officer and Principal Accounting Officer.

     

    Mr. Rosinack, age 53, has served as the Company’s Senior Vice President, Finance since September 2021. Previously, Mr. Rosinack served in roles at Berkeley Lights, Inc., a publicly traded biotechnology company (merged and acquired by Bruker Corporation), including serving as the Senior Vice President and Chief Accounting Officer and Vice President and Corporate Controller from March 2016 to August 2021. Prior to Berkeley Lights, Inc., from October 2012 to March 2016, Mr. Rosinack held roles of increasing responsibility at ZELTIQ Aesthetics, Inc., a publicly traded medical device company (acquired by Allergan plc), including as Vice President and Corporate Controller. Mr. Rosinack also held roles at FormFactor, Inc., a publicly traded semiconductor test and measurement equipment manufacturing company, from April 2011 to October 2012, including as Corporate Controller and Director, Corporate Accounting. In addition, Mr. Rosinack spent more than 14 years in public accounting practice with PricewaterhouseCoopers LLP. Mr. Rosinack received his B.A. in Accounting from Ohio Wesleyan University.

     

    There are no arrangements or understandings between Mr. Rosinack and any other persons in connection with Mr. Rosinack’s appointment as interim Principal Financial Officer and Principal Accounting Officer. There are also no family relationships between Mr. Rosinack and any director or executive officer of the Company and Mr. Rosinack has no direct or indirect interest in any transaction or proposed transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: July 3, 2025 IOVANCE BIOTHERAPEUTICS, INC.
       
       
      By: /s/ Frederick G. Vogt
        Frederick G. Vogt, Ph.D., J.D., Interim CEO and President, and General Counsel

     

     

    Get the next $IOVA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $IOVA

    DatePrice TargetRatingAnalyst
    5/16/2025$2.00Buy → Neutral
    UBS
    5/12/2025Buy → Hold
    Truist
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    10/24/2024$17.00Buy
    UBS
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    11/20/2023$12.00Buy
    Goldman
    9/18/2023$40.00 → $18.00Overweight
    Barclays
    5/30/2023$11.00 → $17.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $IOVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Countouriotis Athena

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/17/25 4:09:11 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Maynard Ryan D

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/17/25 4:08:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Weiser Michael

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/17/25 4:07:54 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iovance Biotherapeutics downgraded by UBS with a new price target

      UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

      5/16/25 8:01:50 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Truist

      Truist downgraded Iovance Biotherapeutics from Buy to Hold

      5/12/25 8:21:43 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Citizens JMP

      Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform

      5/9/25 8:42:44 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 20, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance's common stock to 58 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2

      6/23/25 4:05:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Present at Upcoming Conference

      SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc.  Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and deliver

      6/10/25 8:45:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

      One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that the Journal of Clinical Oncology has published the final analysis from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi® (lifileucel) in patient

      6/2/25 9:29:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/6/25 4:05:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Regulatory Officer Puri Raj K. bought $9,743 worth of shares (5,600 units at $1.74), increasing direct ownership by 3% to 206,852 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/27/25 4:06:43 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/16/25 4:05:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    SEC Filings

    See more
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      7/3/25 4:05:53 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      6/13/25 5:15:24 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      6/10/25 5:15:17 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Financials

    Live finance-specific insights

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

      Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym

      11/7/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IOVA
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $IOVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      10/18/24 8:38:16 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      3/19/24 5:19:45 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care